File No: STD/1257

September 2007

NATIONAL INDUSTRIAL CHEMICALS NOTIFICATION AND ASSESSMENT SCHEME (NICNAS)

FULL PUBLIC REPORT

XP 338

This Assessment has been compiled in accordance with the provisions of the *Industrial Chemicals (Notification and Assessment) Act 1989* (Cwlth) (the Act) and Regulations. This legislation is an Act of the Commonwealth of Australia. The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) is administered by the Department of Health and Ageing, and conducts the risk assessment for public health and occupational health and safety. The assessment of environmental risk is conducted by the Department of the Environment and Water Resources.

For the purposes of subsection 78(1) of the Act, this Full Public Report may be inspected at our NICNAS office by appointment only at 334-336 Illawarra Road, Marrickville NSW 2204.

This Full Public Report is also available for viewing and downloading from the NICNAS website or available on request, free of charge, by contacting NICNAS. For requests and enquiries please contact the NICNAS Administration Coordinator at:

Street Address: 334 - 336 Illawarra Road MARRICKVILLE NSW 2204, AUSTRALIA.

Postal Address: GPO Box 58, SYDNEY NSW 2001, AUSTRALIA.

TEL: + 61 2 8577 8800 FAX + 61 2 8577 8888 Website: www.nicnas.gov.au

Director NICNAS

TABLE OF CONTENTS

| FULI | L PUBLI | IC REPORT | 3 |
|-------|----------------|--|----|
| 1. | APP | LICANT AND NOTIFICATION DETAILS | 3 |
| 2. | IDEN | NTITY OF CHEMICAL | 3 |
| 3. | COM | MPOSITION | 3 |
| 4. | PHY | SICAL AND CHEMICAL PROPERTIES | 4 |
| 5. | INTI | RODUCTION AND USE INFORMATION | 4 |
| 6. | HUM | MAN HEALTH IMPLICATIONS | 5 |
| | 6.1. | Exposure assessment | 5 |
| | 6.1.1 | | |
| | 6.1.2 | Public exposure | 6 |
| | 6.2. | Human health effects assessment | 6 |
| | 6.3. | Human health risk characterisation | 7 |
| | 6.3.1 | . Occupational health and safety | 7 |
| | | Public health | |
| 7. | ENV | TRONMENTAL IMPLICATIONS | 8 |
| | 7.1. | Environmental Exposure & Fate Assessment | 8 |
| | 7.1.1 | Environmental Exposure | 8 |
| | 7.1.2 | Environmental fate | 8 |
| | 7.1.3 | Predicted Environmental Concentration (PEC) | 8 |
| | 7.2. | Environmental effects assessment | 8 |
| | 7.2.1 | Predicted No-Effect Concentration (PNEC) | 8 |
| | 7.3. | Environmental risk assessment | |
| - | | ICLUSIONS – SUMMARY OF RISK ASSESSMENT FOR THE ENVIRONMENT A | |
| Н | JMAN I | HEALTH | |
| | 8.1. | Hazard classification. | |
| | 8.2. | Human health risk assessment | |
| | 8.2.1 | r | |
| | | Public health | |
| | 8.3. | Environmental risk assessment | |
| 9. | | FERIAL SAFETY DATA SHEET | |
| 10 | | ECOMMENDATIONS | |
| 11 | | EGULATORY OBLIGATIONS | |
| | | PHYSICO-CHEMICAL PROPERTIES | |
| APPE | | TOXICOLOGICAL INVESTIGATIONS | |
| | B.1. | Acute toxicity – oral | |
| | B.2. | Acute toxicity – dermal | |
| | B.3. | Irritation – skin | |
| | B.4. | Irritation – eye | |
| | B.5. | Skin sensitisation – mouse local lymph node assay (LLNA) | |
| | B.6. | Repeat dose toxicity | |
| | B.7. | Genotoxicity – bacteria | |
| A DDE | B.8. | Genotoxicity – in vitro | |
| APPE | | ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS | |
| | C.1. | Environmental Fate | |
| | C.1.1 C.1.2 | | |
| | C.1.2 | Ecotoxicological Investigations | |
| | C.2. | | |
| | C.2.1 | | |
| | C.2.3 | J | |
| | C.2.4 | e e | |
| Drorr | C.Z.T | · | 25 |

FULL PUBLIC REPORT

XP 338

1. APPLICANT AND NOTIFICATION DETAILS

APPLICANT(S)

Rhodia Australia Pty Ltd. (ABN 24 050 029 000) of Building 25, Omnico Business Park, 270 Ferntree Gully Road, Notting Hill VIC 3168

NOTIFICATION CATEGORY

Standard: Chemical other than polymer (more than 1 tonne per year)

EXEMPT INFORMATION (SECTION 75 OF THE ACT)

Data items and details claimed exempt from publication:

Chemical name, CAS number, Molecular formula, Structural formula, Molecular weight, Spectral data, Purity, Identity of toxic or hazardous impurities, %Weight of toxic or hazardous impurities, Non-hazardous impurities, Identity of additives/adjuvants, %Weight of additives/adjuvants, and Manufacture/import volume

VARIATION OF DATA REQUIREMENTS (SECTION 24 OF THE ACT)

Variation to the schedule of data requirements is claimed as follows:

Water solubility, Partition coefficient, Absorption/desorption, Dissociation constant, Particle size, Flash point, Flammability limits, and Explosive properties.

PREVIOUS NOTIFICATION IN AUSTRALIA BY APPLICANT(S)

None

NOTIFICATION IN OTHER COUNTRIES UK HSE (2004)

2. IDENTITY OF CHEMICAL

OTHER NAME(S)

None

MARKETING NAME(S)

XP 338

MOLECULAR WEIGHT

<500 Da

ANALYTICAL DATA

Reference NMR, IR, and UV spectra, and microanalysis data were provided.

3. COMPOSITION

DEGREE OF PURITY >95%

4. PHYSICAL AND CHEMICAL PROPERTIES

Appearance at 20°C and 101.3 kPa

Pale yellow crystalline solid

| Property | Value | Data Source/Justification |
|---|--|---|
| Melting Point | ~300°C (with decomposition) | Measured |
| Boiling Point | 359°C at 102.57 kPa | Calculated |
| Density | $1,210 \text{ kg/m}^3 \text{ at } 21^{\circ}\text{C}$ | Measured |
| Vapour Pressure | $2.5{\times}10^{-16}~kPa$ at $25^{o}C$ | Measured |
| Water Solubility | Not determined | Rapidly hydrolysable in water |
| Hydrolysis as a Function of pH | $t^{1/2} < 1$ hour (pH 4, 7, and 9) | Measured |
| Partition Coefficient (n-octanol/water) | Not determined | Rapidly hydrolysable in water |
| Adsorption/Desorption | Not determined | Rapidly hydrolysable in water |
| Dissociation Constant | Not determined | Rapidly hydrolysable in water, and has no known modes of dissociation |
| Particle Size | Not determined | Imported only as a solution in petroleum distillates (bp ~250°C) |
| Flash Point | Not determined | The notified chemical is a solid with a low vapour pressure |
| Flammability | Not highly flammable | Measured |
| Autoignition Temperature | No self-ignition occurred below the melting temperature. | Measured |
| Explosive Properties | Not expected to be explosive | Calculated |

Discussion of Observed Properties

For full details of the physical-chemical properties tests please refer to Appendix A.

Reactivity

From experience in use and from the chemical structure, the notified chemical does not lead to the development of dangerous amounts of flammable gases in contact with water or moist air, and is not flammable in contact with air (pyrophoric).

The notified chemical does not possess oxidising properties on the basis of experience in use and from its chemical structure. The oxygen balance for the representative structure of the notified chemical is - 164, and it does not contain any functional groups that might indicate an oxidant.

Dangerous Goods classification

Based on the available physico-chemical properties the notified chemical is not classified as a Dangerous Good according to the Australian Dangerous Goods Code (FORS, 1998).

5. INTRODUCTION AND USE INFORMATION

Mode of Introduction of Notified Chemical (100%) Over Next 5 Years

The notified chemical will not be manufactured in Australia, but imported as a \sim 50% formulation in a petroleum distillate.

MAXIMUM INTRODUCTION VOLUME OF NOTIFIED CHEMICAL (100%) OVER NEXT 5 YEARS

| Year | 1 | 2 | 3 | 4 | 5 |
|--------|-------|-------|-------|-------|-------|
| Tonnes | 10-50 | 10-50 | 10-50 | 10-50 | 10-50 |

PORT OF ENTRY

The notified notified chemical will be imported through Melbourne by wharf.

IDENTITY OF MANUFACTURER/RECIPIENTS Rhodia Australia Pty Ltd. Building 25, Omnico Business Park 270 Ferntree Gully Road Notting Hill VIC 3168

TRANSPORTATION AND PACKAGING

The notified chemical is imported into Australia only as a formulation in a petroleum distillate (boiling point ~250°C). The import containers are 55 US gallon (205 L) steel drums. The notified chemical will be transported from the point of importation to the recipients by road.

Use

The notified chemical will be used as a viscosity control agent to formulate ink vehicles (also known as "varnishes") for the production of lithographic printing inks. The notified chemical will typically be added to ink vehicles at a concentration of <2%. During formulation of the vehicle, the notified chemical reacts with other ink vehicle components, losing its chemical identity.

The ink vehicles will be used to produce lithographic printing inks, which are typically used in the printing of high quality, high gloss magazines.

OPERATION DESCRIPTION

Formulation of ink vehicles (varnishes)

Typically, the petroleum distillate preparation containing the notified chemical at \sim 50% would be pumped from a drum into a pre-dilution tank, or directly into the varnish kettle. A typical varnish kettle is a closed reactor-type tank, with a condenser to catch any volatiles. The varnish is typically composed of drying oils, petroleum oils, and various rosin/phenolic and alkyd resins. During formulation of the ink vehicles, the chemical identity of the notified chemical is lost by reaction, and the chemical itself is therefore not present during the subsequent processes of ink manufacturing and printing.

6. HUMAN HEALTH IMPLICATIONS

6.1. Exposure assessment

6.1.1. Occupational exposure

Number and Category of Workers

| Category of Worker | Number | Exposure Duration | Exposure Frequency |
|--------------------|--------|-------------------|--------------------|
| Process operator | 1 | 15 min | 1/day |

Exposure Details

The exposure of transport and storage workers is only expected in the unlikely event of a significant industrial accident, where rupture of the steel drums occurred.

The only significant exposure of workers might occur to the imported notified chemical solution (\sim 50% concentration) during hose attachment/detachment and pumping operations for ink vehicle formulation. This exposure is expected to be primarily dermal or ocular, arising from spills or leaks. During these procedures, appropriate personal protective equipment (PPE) will be worn by workers, such as chemical resistant gloves (eg neoprene), chemical goggles and overalls. Appropriate industrial hygiene procedures are expected to be implemented during these operations.

The remainder of the formulation process will occur in an enclosed chemical reactor, where very low or no exposure to workers will occur. During formulation, the notified chemical is consumed in the reaction, so no exposure to the notified chemical is expected from subsequent steps in ink vehicle formulation and use.

Ink vehicles (and therefore inks) may contain the hydrolysis products of the notified chemical. Therefore, ink manufacturing and lithographic printing workers may also be exposed to these chemicals (at <2% in ink vehicles). This exposure is likely to primarily dermal and possibly ocular. In addition, traces of these hydrolysis products may remain on printed media, which might result in dermal exposure of other workers such as printed media distributors and retailers. These species are

volatile, and therefore dry printed pages are not expected to contain significant levels.

6.1.2. Public exposure

The notified chemical will not be sold directly to members of the public, but will be used in the formulation of ink vehicles that in turn will be used for printing media for use by members of the public. However, the notified chemical will be consumed during the industrial process of ink vehicle formulation, and it is therefore not expected to be present in either the printing inks or in any printed media that is available to the public.

Ink vehicles (and therefore inks) may contain the hydrolysis products of the notified chemical (at <2%), and traces of these may remain on printed media available for public use. These species are volatile, and therefore dry printed pages are not expected to contain significant levels.

6.2. Human health effects assessment

The results from toxicological investigations conducted on the notified chemical or on a structurally related analogue ("XP 339") are summarised in the table below. The notifier stated that the rat acute oral LD_{50} of XP 339 was >2,500 mg/kg – identical to that of the notified chemical. In addition, the differences between the two chemicals were analysed in relation to their expected physicochemical properties and toxicological profiles. The two chemicals were found to be sufficiently similar for assessment by analogy. The details of the toxicological investigations can be found in Appendix B.

| Endpoint | Test substance | Result and Assessment Conclusion |
|---|-------------------|---|
| Rat, acute oral toxicity | Notified chemical | Low toxicity, LD ₅₀ >2,500 mg/kg bw |
| Rat, acute dermal toxicity | XP 339 | Low toxicity, LD ₅₀ >2,000 mg/kg bw |
| Rabbit, skin irritation | XP 339 | Slightly irritating |
| Rabbit, eye irritation | XP 339 | Slightly irritating |
| Mouse, Local Lymph Node Assay (LLNA) | XP 339 | No evidence of sensitisation. |
| Rat, oral repeat dose toxicity - 90 days | XP 339 | NOAEL = 1,000 mg/kg bw/day (NOEL not established) |
| Mutagenicity (bacterial reverse mutation) | Notified chemical | Non-mutagenic |
| Genotoxicity (in vitro chromosome aberration) | XP 339 | Non-genotoxic |

Toxicokinetics, metabolism and distribution

Given its reactive nature, the notified chemical is not likely to be significantly absorbed following exposure by any route. Any absorption would result in rapid hydrolysis to yield simple, well-defined chemicals (see below for some information on the general toxicity of these).

Due to its reactivity, the toxicity of the notified chemical is expected to be restricted to local irritative effects, where it might be expected to react with surface molecules of skin or mucous membranes. The production of hydrolysis products may also contribute to its irritative properties.

The analogue of the notified chemical, "XP 339", is expected to hydrolyse at an equivalent rate to the notified chemical upon administration and/or contact with water.

Acute and repeated dose toxicity

Generally, the notified chemical or its analogue was found to be of low acute oral and dermal toxicity. No signs of toxicity were observed after an acute exposure.

In a 90-day oral repeated-dose toxicity study, the analogue of the notified chemical induced minor effects or no significant effects. Most of the observed effects can be related to the irritant nature of the analogue of the notified chemical.

Irritation and sensitisation

Slight irritation was observed upon acute administration of the analogue of the notified chemical to eye or skin. Irritant effects were also observed in the repeat dose toxicity study upon microscopic

examination of the stomach and trachea of gavage-treated rats. The analogue of the notified chemical might be expected to be more irritating than the notified chemical, based on the available toxicological data determined for the hydrolysis products of each.

The analogue of the notified chemical was not sensitising in a mouse LLNA assay.

Mutagenicity and Genotoxicity

The weight of evidence from the two *in vitro* studies suggests that the notified chemical is not likely to be mutagenic or genotoxic.

Observations on human exposure

No human health conditions have been reported to be associated with exposure to the notified chemical.

Hydrolysis products

The from the data available in the literature, the hydrolysis products of the notified chemical are generally of low toxicity, and their toxic effects are expected to be limited to mild-moderate irritative effects on skin and eye. This hypothesis is supported by the toxicological data available for the notified chemical and its analogue, XP 339. Based on the known toxicological data for the hydrolysis products of the analogue of the notified chemical, it is expected to perhaps higher toxicity (though still low), and possibly more severe irritative characteristics.

Based on the available data, the notified chemical is not classified as hazardous under the NOHSC *Approved Criteria for Classifying Hazardous Substances* (NOHSC, 2004).

6.3. Human health risk characterisation

6.3.1. Occupational health and safety

The only significant occupational exposure to the notified chemical is likely to occur during the formulation of ink vehicles, during hose attachment and pumping operations. During these procedures, the use of appropriate PPE and good industrial hygiene procedures should ensure that exposure is minimal. The toxicological profile of the notified chemical and its analogue is suggestive of a probable low hazard. Therefore, the notified chemical is unlikely to pose a significant risk to process operators involved in ink vehicle formulation.

The risk to ink manufacturing or lithographic printing workers from the notified chemical is negligible, as the chemical will not be present in ink vehicles after formulation. These workers may experience exposure to the hydrolysis products of the notified chemical. The risk from these hydrolysis products in ink vehicles is likely to be low, due to their low concentration (<2%). The possibility of irritant effects to workers may be significant, but given the other components of the ink vehicles this would be a known hazard in the use of such products. Appropriate measures (eg appropriate PPE and physical containment) are expected to be implemented where these inks will be used. Therefore, the overall risk to workers from the use of ink vehicles is expected to be acceptable.

The likelihood of exposure of distribution and retail workers to the hydrolysis products of the notified chemical from printed media is expected to be negligible, given the volatile nature and low toxicity of these species. Their potential for irritant effects are not likely to be a concern from dried, printed pages at the concentrations proposed.

6.3.2. Public health

The notified chemical will be used in the formulation of ink vehicles that will be used for printing media that is intended for public consumption. However, the notified chemical will be consumed during the industrial process of ink vehicle formulation, and it is therefore not expected to be present in the printing inks or in any printed media that is available to the public.

The hydrolysis products may be present in formulated ink vehicles, and thus may remain on printed surfaces. However, these species will be present at low concentrations in the ink vehicles (<2%), are volatile, and are of low toxicity. The potential for irritant effects are not likely to be a concern from dried, printed pages at the concentrations proposed.

Therefore, due to the negligible public exposure to the notified chemical in the proposed use, it is not considered to pose a significant risk to public health.

7. ENVIRONMENTAL IMPLICATIONS

7.1. Environmental Exposure & Fate Assessment

7.1.1 Environmental Exposure

RELEASE OF CHEMICAL AT SITE

The notified chemical in petroleum distillate (\sim 50%) will be imported from overseas and is used in the formulation of the printing ink vehicles.

During the formulation process, the notified chemical reacts with the resins resulting in the irreversible formation of acylate linkages. On this basis, the notified chemical is not present in the preparation following formulation of the vehicles. There is scope for accidental spillage to occur while loading the notified chemical into the formulation kettle, which is a closed reactor-type tank with a condenser to catch any volatiles. Should a spill occur it would be contained to the plant by bunding.

It is expected that up to 2% of the residues will remain in the imported container. The residues in the container will be cleaned with aqueous media resulting in the hydrolysis of the notified chemical to its components. When cleaned with solvents, the residues would be expected to be incinerated. Empty drums may be returned to the supplier or be sent for cleaning and re-conditioning.

RELEASE OF CHEMICAL FROM USE

As the notified chemical is not present in the final printing ink, there are no further environmental implications from the proposed use.

RELEASE OF CHEMICAL FROM DISPOSAL

It is anticipated that up to 2% of the notified chemical will be lost as residues in imported container, which are primarily disposed of by incineration.

7.1.2 Environmental fate

For the details of the environmental fate studies, please refer to Appendix C. The notified chemical is not soluble in water, but rapidly hydrolyses upon contact with water. It is readily biodegradable. As the notified chemical is not present in the formulated product, the only environmental release is prior to the formulation process. Such releases may result from incineration, resulting in the formation of oxides of carbon and aluminium and water, or from hydrolysis of the notified chemical.

7.1.3 Predicted Environmental Concentration (PEC)

As the notified chemical is not present in the formulated product, there is no aquatic release from the proposed use. Therefore, a PEC value cannot be calculated.

7.2. Environmental effects assessment

The results from ecotoxicological investigations conducted on the notified chemical are summarised in the table below. Details of these studies can be found in Appendix C.

| Endpoint | Result | Assessment Conclusion |
|-------------------------------------|--|-----------------------|
| Fish Toxicity | 96 h EC ₅₀ >100 mg/L | Non-toxic |
| Daphnia Toxicity | $48 \text{ h EC}_{50} = 35 \text{ mg/L}$ | Harmful |
| Algal Toxicity | 72 h ErC ₅₀ >320 mg/L | Non-toxic |
| Inhibition of Bacterial Respiration | $EC_{50} > 1,000 \text{ mg/L}$ | Non-toxic |

These results indicate that the notified chemical or its hydrolysed products are harmful to *Daphnia magna*.

7.2.1 Predicted No-Effect Concentration (PNEC)

The Predicted No-Effect Concentration has been calculated from the most sensitive *Daphnia magna* toxicity (48 h $EC_{50} = 35 \text{ mg/L}$) of the notified chemical. As the results are available for three trophic levels, an assessment factor of 100 has been used.

| PNEC for the Aquatic Compartment | | |
|--|------|------|
| 48 h EC ₅₀ for <i>Daphnia magna</i> | 35 | mg/L |
| Assessment Factor | 100 | |
| Mitigation Factor | 1.00 | |
| PNEC | 350 | μg/L |

7.3. Environmental risk assessment

The majority of the notified chemical will be consumed during the formulation process and will not be present in the formulated product. Therefore, minimal environmental exposure is likely to occur. Its use in industrial settings and consumption in the industrial process is unlikely to have an adverse effect on aquatic organisms.

The likely route of environmental exposure is from accidental spillage and washing of the used import container. In the case of spillage, it would be contained to the plant by bunding. The residues from the washing of containers will be collected and eventually be incinerated with the generation of oxides of carbon and metal and water or be hydrolysed in aqueous media.

Given its limited environmental exposure, the notified chemical is unlikely to pose an environmental risk under the proposed use pattern.

8. CONCLUSIONS – SUMMARY OF RISK ASSESSMENT FOR THE ENVIRONMENT AND HUMAN HEALTH

8.1. Hazard classification

Based on the available data the notified chemical is not classified as hazardous under the *Approved Criteria for Classifying Hazardous Substances*.

and

As a comparison only, the classification of notified chemical using the Globally Harmonised System for the Classification and Labelling of Chemicals (GHS) (United Nations 2003) is presented below. This system is not mandated in Australia and carries no legal status but is presented for information purposes.

| | Hazard category | Hazard statement |
|----------------------|-----------------|------------------|
| Environmental Hazard | Acute III | Harmful |

8.2. Human health risk assessment

8.2.1. Occupational health and safety

Under the conditions of the occupational settings described, the risk to workers is considered to be acceptable.

8.2.2. Public health

When used in the proposed manner, the risk to the public is considered to be acceptable.

8.3. Environmental risk assessment

The chemical is not considered to pose a risk to the environment based on its reported use pattern.

9. MATERIAL SAFETY DATA SHEET

The MSDS of the notified chemical, provided by the notifier, is published here as a matter of public record. The accuracy of the information on the MSDS remains the responsibility of the applicant.

10. RECOMMENDATIONS

CONTROL MEASURES
Occupational Health and Safety

• Employers should implement the following safe work practices to minimise occupational exposure during handling of the notified chemical solution as introduced:

- Avoid spills and skin or eye contact
- Employers should ensure that the following personal protective equipment is used by workers to minimise occupational exposure to the notified chemical solution as introduced:
 - Chemical resistant gloves, chemical goggles and overalls

Guidance in selection of personal protective equipment can be obtained from Australian, Australian/New Zealand or other approved standards.

- A copy of the MSDS should be easily accessible to employees.
- If products and mixtures containing the notified chemical are classified as hazardous to health in accordance with the *Approved Criteria for Classifying Hazardous Substances*, workplace practices and control procedures consistent with provisions of State and Territory hazardous substances legislation must be in operation.

Disposal

• The notified chemical should be disposed of by landfill.

Emergency procedures

- Prevent leakage of large quantities into the drainage system by bunding with sand or other absorbent material. In the event of large spills contact emergency services and the local authorities.
- Ventilate area and try to contain spill by diking with sand or other absorbent material. Collect spill for disposal by scooping up liquids, using a vacuum pump, or absorbing with sand or other approved absorbent materials and place in suitably labelled container for disposal in accordance with local and national regulations. Contact authorities and wastewater treatment plant as appropriate if significant contamination occurs.

11. REGULATORY OBLIGATIONS

This risk assessment is based on the information available at the time of notification. The Director may call for the reassessment of the chemical under secondary notification provisions based on changes in certain circumstances. Under Section 64 of the *Industrial Chemicals (Notification and Assessment) Act (1989)* the notifier, as well as any other importer or manufacturer of the notified chemical, have post-assessment regulatory obligations to notify NICNAS when any of these circumstances change. These obligations apply even when the notified chemical is listed on the Australian Inventory of Chemical Substances (AICS).

Therefore, the Director must be notified in writing within 28 days by the notifier, other importer or manufacturer:

- (1) Under Section 64(1) of the Act; if
 - The notified chemical is imported in a solid physical state. If importation of a solid is intended, particle size data should be provided.

or

- (2) Under Section 64(2) of the Act; if
 - the function or use of the chemical has changed from a component of ink vehicle

- formulations, or is likely to change significantly;
- the amount of chemical being introduced has increased from 50 tonnes, or is likely to increase, significantly;
- if the chemical has begun to be manufactured in Australia;
- additional information has become available to the person as to an adverse effect of the chemical on occupational health and safety, public health, or the environment.

The Director will then decide whether a reassessment (i.e. a secondary notification and assessment) is required.

APPENDIX A: PHYSICO-CHEMICAL PROPERTIES

Melting Point ~300°C (with decomposition)

METHOD EC Directive 92/69/EEC A.2 Melting/Freezing Temperature.

Remarks Measured by Differential Scanning Calorimetry (DSC) at 102.57 kPa

TEST FACILITY SafePharm (2004a)

Boiling Point ~359°C at 102.57 kPa

METHOD Calculation.

Remarks The test material decomposed, no value for boiling temperature could be

determined by DSC.

TEST FACILITY SafePharm (2004a)

Density $1,210 \text{ kg/m}^3 \text{ at } 21^{\circ}\text{C}$

METHOD EC Directive 92/69/EEC A.3 Relative Density.

Remarks Determined using a gas comparison pycnometer.

TEST FACILITY SafePharm (2004a)

Vapour Pressure 2.5×10^{-16} kPa at 25°C

METHOD EC Directive 92/69/EEC A.4 Vapour Pressure.

Remarks Determined by worst-case extrapolation from experimental (vapour pressure

balance) data with low correlation.

TEST FACILITY SafePharm (2004b)

Hydrolysis as a Function of pH

METHOD EC Directive 92/69/EEC C.7 Degradation: Abiotic Degradation: Hydrolysis as a

Function of pH.

| рН | T (°C) | t½ (hours) |
|----|--------|------------|
| 4 | 50 | <1 |
| 7 | 50 | <1 |
| 9 | 50 | <1 |

chemical was added to de-ionised water preheated to 50°C at pH 4.0, 7.0 and 9.0. Samples were periodically removed, microfiltered and analysed by gas chromatography. The hydrolysis was measured by analysing for its hydrolysed

products.

The notified chemical hydrolysed rapidly on contact with water. At pH 9, >90% of a hydrolysis product was recovered within the first hour. At pH 7, again >90% of the hydrolysis product was recovered in less than one hour. The data obtained at

pH 4 was very similar to that obtained at pH 7.0.

It was evident that 50% or more of the notified chemical had been hydrolysed

within the 2.4 hour time limit of the test guideline, at 50°C at pH 4, 7 and 9.

TEST FACILITY FedChem (2003c)

Flammability (solids) Not highly flammable.

METHOD EC Directive 92/69/EEC A.10 Flammability (Solids)

Remarks The solid notified chemical ignited upon application of an air-rich bunsen flame,

and propagated combustion over 200 mm in 34 min 42 sec.

The moisture content of the solid notified chemical was determined to be 3.8% by drying to constant weight at 105°C. This loss of mass may be attributed in part to

the loss of volatiles resulting from surface hydrolysis.

TEST FACILITY SafePharm (2004b)

Autoignition Temperature

No self-ignition occurred below the melting temperature.

METHOD 92/69/EEC A.16 Relative Self-Ignition Temperature for Solids.

Remarks None.

TEST FACILITY SafePharm (2004b)

Explosive Properties

Remarks The notified chemical is not expected to be explosive on the basis of experience in

use, its known thermal properties, and from its chemical structure. The oxygen balance for the representative structure is -164, and it contains no explosophores.

APPENDIX B: TOXICOLOGICAL INVESTIGATIONS

Note: Several studies were performed using a related chemical, "XP 339", that is an acceptable, structurally related analogue of the notified chemical.

B.1. Acute toxicity – oral

TEST SUBSTANCE Notified chemical (solid)

METHOD OECD TG 423 Acute Oral Toxicity – Acute Toxic Class Method.

Species/Strain Rat/Sprague-Dawley CD

Vehicle Arachis oil BP

Remarks – Method No significant protocol deviations.

RESULTS

| Dose (mg/kg bw) | Number and Sex of Animals | Mortality | |
|--|--|--|--|
| 2,000 | 6F | 0 | |
| LD ₅₀ Signs of Toxicity Effects in Organs Remarks – Results | >2,500 mg/kg bw There were no signs of systemic No abnormalities were noted up The LD ₅₀ was set using the flov and was based on the absence of | on necropsy. v chart of Annex 2d of the t | |
| CONCLUSION | The notified chemical is of low | toxicity via the oral route. | |
| TEST FACILITY | SafePharm (2004c) | | |

B.2. Acute toxicity – dermal

TEST SUBSTANCE XP 339

METHOD OECD TG 402 Acute Dermal Toxicity.

EC Directive 92/69/EEC B.3 Acute Toxicity (Dermal).

Species/Strain Rat/Sprague-Dawley CD

Vehicle Arachis oil BP
Type of dressing Semi-occlusive

Remarks – Method No significant protocol deviations.

RESULTS

| Dose (mg/kg bw) | Number and Sex of Animals | Mortality | |
|--|--|---|--|
| 2000 | 3M, 3F | 0 | |
| LD50 | >2,000 mg/kg bw | | |
| Signs of Toxicity - Local | No signs of dermal irritation were of | observed. | |
| Signs of Toxicity - Systemic | <u> </u> | est animals showed the expected gains | |
| Effects in Organs Remarks – Results | No abnormalities were noted at necropsy. | | |
| Conclusion | The analogue of the notified chemroute. | nical is of low toxicity via the dermal | |
| TEST FACILITY | SafePharm (2004d) | | |

B.3. Irritation – skin

TEST SUBSTANCE XP 339 (solid)

METHOD OECD TG 404 Acute Dermal Irritation/Corrosion.

EC Directive 92/69/EEC B.4 Acute Toxicity (Skin Irritation).

Species/Strain Rabbit/New Zealand White

Number of Animals 3

Vehicle Arachis oil BP
Observation Period 72 hours
Type of Dressing Semi-occlusive

Remarks – Method No significant protocol deviations

RESULTS

| Lesion | Mean Score* Animal No. | | Maximum Value | Maximum Duration of Any Effect | Maximum Value at End of Observation Period | |
|-----------------|---------------------------|------|------------------|--------------------------------|---|---|
| | 1 | 2 | 3 | | | |
| Erythema/Eschar | 0.66 | 0.66 | 0.66 | 1 | 48 hours | 0 |
| Oedema | 0 | 0 | 0 | 0 | - | 0 |

^{*}Calculated on the basis of the scores at 24, 48, and 72 hours for each animal.

Remarks – Results Primary irritation index of 0.5 (mild irritant on Draize classification).

No corrosive effects were noted.

CONCLUSION The notified chemical is slightly irritating to skin.

TEST FACILITY SafePharm (2004e)

B.4. Irritation – eye

TEST SUBSTANCE XP 339 (solid)

METHOD OECD TG 405 Acute Eye Irritation/Corrosion.

EC Directive 92/69/EEC B.5 Acute Toxicity (Eye Irritation).

Species/Strain Rabbit/New Zealand White

Number of Animals

Observation Period 72 hours

Remarks – Method No significant protocol deviations.

3

RESULTS

| Lesion | | ean Scor nimal N | | Maximum Value | Maximum Duration of Any Effect | Maximum Value at End of Observation Period |
|------------------------|---|---------------------|---|------------------|--------------------------------------|--|
| | 1 | 2 | 3 | | | |
| Conjunctiva: redness | 0 | 0 | 0 | 1 | 1 hour | 0 |
| Conjunctiva: chemosis | 0 | 0 | 0 | 1 | 1 hour | 0 |
| Conjunctiva: discharge | 0 | 0 | 0 | 1 | 1 hour | 0 |
| Corneal opacity | 0 | 0 | 0 | 0 | 0 | 0 |
| Iridial inflammation | 0 | 0 | 0 | 0 | 0 | 0 |

^{*}Calculated on the basis of the scores at 24, 48, and 72 hours for each animal.

Remarks – Results Minimal conjunctival irritation was observed one hour after treatment.

All eyes appeared normal after 24 hours.

CONCLUSION The notified chemical is slightly irritating to the eye.

TEST FACILITY SafePharm (2004f)

B.5. Skin sensitisation – mouse local lymph node assay (LLNA)

TEST SUBSTANCE XP 339 (solid)

METHOD OECD 429 Skin Sensitisation: Local Lymph Node Assay

Species/Strain Mouse/CBA/Ca (CBA/CaBkl)

Vehicle 4:1 acetone:olive oil

Remarks – Method There were no significant protocol deviations.

Groups of five female mice were tested for each concentration

RESULTS

| Concentration | Proliferative response | Stimulation Index |
|---------------|------------------------|----------------------|
| | (DPM/lymph node) | (Test/Control Ratio) |
| 0 (control) | 967 | 0 |
| 5 | 1658 | 1.72 |
| 10 | 2341 | 2.42 |
| 25 | 1938 | 2.00 |

generated a positive response at a concentration of 25%.

CONCLUSION There was no evidence of induction of a lymphocyte proliferative

response indicative of skin sensitisation to the notified chemical.

TEST FACILITY SafePharm (2004g)

B.6. Repeat dose toxicity

TEST SUBSTANCE XP 339 (solid)

METHOD OECD TG 408 Repeated Dose 90-Day Oral Toxicity Study in Rodents.

Species/Strain Rat/Sprague-Dawley Crl:CD (SD) IGS BR

Route of Administration Oral – gavage

Exposure Information Total exposure days: 90 days
Dose regimen: 7 days per week.

There was no post-exposure observation period.

Vehicle Arachis oil BP

Remarks – Method No significant protocol changes.

RESULTS

| Dose (mg/kg bw/day) | Number and Sex of Animals | Mortality |
|---------------------|---------------------------|-----------|
| 0 (control) | 10M, 10F | 0 |
| 50 | 10M, 10F | 0 |
| 250 | 10M, 10F | 0 |
| 1,000 | 10M, 10F | 0 |

Mortality and Time to Death

No deaths were observed during the study period.

Clinical Observations

No clinically observable signs of toxicity were observed. Incidental findings at 250 and 1,000 mg/kg bw/day included hunched posture, noisy respiration and red/brown staining around the eyes. These effects were deemed to be due to oral administration of an unpalatable or irritant substance, and not indicative of systemic toxicity.

There were no treatment-related effects on behaviour, functional performance, sensory reactivity, bodyweight, or on food or water consumption.

Laboratory Findings - Clinical Chemistry, Haematology, Urinalysis

There were no treatment-related changes detected in the haematological parameters measured, or in blood chemistry. Females treated with 1,000 mg/kg bw/day showed statistically significant reductions in inorganic phosphorus levels, mean corpuscular volume and mean cell haemoglobin levels, but in isolation these changes were considered not to be of significance. Similarly, a statistically significant increase in plasma glucose was observed in females of the 250 mg/kg bw/day group, but was considered incidental due to the lack of this effect in the higher dose group.

Effects in Organs

No treatment-related organ-weight changes were detected.

No macroscopic abnormalities were detected at terminal kill.

Tracheal epithelial deciliation was observed microscopically in males treated with 250 mg/kg bw/day and all animals treated with 1,000 mg/kg bw/day. Associated epithelial hyperplasia and inflammatory cell infiltrates were also observed. These changes were considered to be due to accidental tracheal administration of the test substance. Agglomeration of secretion was observed in the gastric mucosa of animals treated with 1,000 mg/kg bw/day. Acanthosis and hyperkeratosis of the forestomach epithelium of were also observed.

The absolute adrenal weight was statistically reduced in all treated males. When considered relative to terminal bodyweight, this effect was only significant at 50 and 1,000 mg/kg bw/day, although reduced adrenal weights were also observed at 250 mg/kg bw/day. The reduced significance at this dose may be due to a slightly reduced bodyweight in males treated with the highest two dose levels (not otherwise significant). This result was considered by the investigators to be of no toxicological significance, due to the lack of correlating histopathological findings and due to the lack of an apparent dose-response. However, the latter argument may be flawed, as an effect on adrenal weight may have occurred at all doses ≥50 mg/kg bw/day.

One female treated with 1,000 mg/kg bw/day showed an enlarged, discoloured and fluid-filled kidney upon necropsy that was found to be due to a malignant tubular carcinoma. This result was considered to have been spontaneous and of no toxicological significance

Remarks – Results

The microscopic gastric and tracheal changes seen at 250 and/or 1,000 mg/kg bw/day, together with associated incidental clinical findings, were considered due to the irritant nature of the test material, and were considered not to represent a true systemic effect. Exclusion of the findings associated with irritancy results in a NOAEL of 1,000 mg/kg bw/day.

The study investigators stated their No Observed Effect Level (NOEL) to have been established as 50 mg/kg bw/day. However, the justification for this NOEL value is not considered accurate, as the effects on adrenal weight observed in males at all doses are considered to be of relevance.

CONCLUSION

The No Observed Adverse Effect Level (NOAEL) was established as 1,000 mg/kg bw/day. The No Observed Effect Level (NOEL) could not be established from the results presented in this study.

TEST FACILITY SafePharm (2004h)

B.7. Genotoxicity – bacteria

TEST SUBSTANCE Notified chemical (solid)

METHOD OECD TG 471 Bacterial Reverse Mutation Test.

Plate incorporation procedure

Species/Strain

S. typhimurium: TA1535, TA1537, TA98, TA100, and TA102

Metabolic Activation System
Concentration Range in Main

S. typhimurium: TA1535, TA1537, TA98, TA100, and TA102

Phenobarbitone/β-naphthoflavone-induced rat liver S9 mix

a) With metabolic activation: 50 to 5,000 μg/plate.

Test b) Without metabolic activation: 50 to 5,000 μg/plate.

Vehicle Aceto

Remarks – Method No significant protocol deviations.

RESULTS

| Met | abolic | Test | Substance Concentrati | ion (μg/plate) Resultii | ng in: |
|---------|--------|------------------|-----------------------|-------------------------|------------------|
| Acti | vation | Cytotoxicity in | Cytotoxicity in | Precipitation | Genotoxic Effect |
| | | Preliminary Test | Main Test | | |
| Present | Test 1 | >5000 | >5000 | 5000 | Negative |
| | Test 2 | | >5000 | 5000 | Negative |
| Absent | Test 1 | >5000 | >5000 | 5000 | Negative |
| | Test 2 | | | 5000 | Negative |

Remarks – Results A slight, shiny precipitate was observed under an inverted microscope at

5,000 μg/plate, but this did not prevent the scoring of revertant colonies.

A small, statistically significant increase (1.18-fold) in revertant colony frequency was observed in TA100 (without S9) at 150 μ g/plate in the first experiment. This increase was considered not to be of biological relevance because of the lack of both dose-response relationship and reproducibility, and because of the small magnitude of the increase.

CONCLUSION The notified chemical was not mutagenic to bacteria under the conditions

of the test.

TEST FACILITY SafePharm (2004i)

B.8. Genotoxicity - in vitro

TEST SUBSTANCE XP 339

METHOD OECD TG 473 In vitro Mammalian Chromosome Aberration Test.

EC Directive 2000/32/EC B.10 Mutagenicity - In vitro Mammalian

Chromosome Aberration Test

Species/Strain Human

Cell Type/Cell Line Peripheral lymphocytes

Metabolic Activation System Phenobarbitone/β-naphthoflavone-induced rat liver S9 mix

Vehicle Dimethylsulfoxide (DMSO)
Remarks – Method No significant protocol deviations.

| Metabolic | | Test Substance Concentration (µg/mL) | Exposure | Harvest |
|-----------|--------|---|----------|---------|
| Acti | vation | | Period | Time |
| Present | Test 1 | 0*, 156.25, 312.5, 625*, 1250*, 1875*, 2500* | 4 | 24 |
| | Test 2 | 0*, 78.13*, 156.25*, 312.5*, 625*, 1250, 2500 | 4 | 24 |
| Absent | Test 1 | 0*, 156.25*, 312.5*, 625* | 4 | 24 |
| | Test 2 | 0*, 156.25*, 312.5*, 625*, 1250, 1875, 2500 | 24 | 24 |

^{*}Cultures selected for metaphase analysis.

RESULTS

| | | Tes | t Substance Concentra | ation (µg/mL) Resultii | ng in: |
|---------|---------------|-----------------|-----------------------|------------------------|------------------|
| Metabol | ic Activation | Cytotoxicity in | Cytotoxicity in | Precipitation | Genotoxic Effect |
| | | PreliminaryTest | Main Test | | |
| Present | Test 1 | ≥2500 | ≥625 | ≥1250 | Negative |
| | Test 2 | | ≥625 | ≥1250 | Negative |
| Absent | Test 1 | ≥625 | >2500 | ≥625 | Negative |
| | Test 2 | | >2500 | ≥625 | Negative |

Remarks - Results

The test substance was toxic to cultured cells, but did not induce chromosomal aberration frequency in two independent experiments. The dose range included a dose level that was either the maximum practical dose, or one that induced a \sim 50% inhibition of the mitotic index.

The positive controls induced the appropriate statistically significant

increases in the frequency of cells with chromosome aberrations.

S9 was present at 2% in Test 1 and 1% in test 2.

CONCLUSION The notified chemical was not clastogenic to human lymphocytes treated

in vitro under the conditions of the test.

TEST FACILITY SafePharm (2004j)

APPENDIX C: ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS

Note: Several studies were performed using a related chemical, "XP 339", that is an acceptable, structurally related analogue of the notified chemical.

C.1. Environmental Fate

C.1.1. Ready biodegradability

TEST SUBSTANCE Notified chemical

METHOD OECD TG 301 F Ready Biodegradability: Manometric Respirometry

Test.

EC Directive 92/69/EEC C.4-D

US EPA Fate, Transport and Transformation Test Guidelines OPPTS

835.3110 Paragraph (q).

Inoculum Activated sludge

Exposure Period 28 d Auxiliary Solvent None Analytical Monitoring BOD

Remarks - Method The test substance was dispersed in culture medium and subject to

ultrasonication prior to the test. The test substance was tested in triplicates at nominal test concentration of 100 mg/L with inoculum for up to 28 days. The test system consisted of the inoculum control, reference substance aniline at 100 mg/L and the toxicity control containing the test substance, reference substance and inoculum. The consumption of oxygen was measured using respirometer and the evolved CO₂ was absorbed in ethanolamine. The amount of O₂ consumed was expressed as % of ThOD calculated from the molecular formulae. The pH and temperatures were

measured during the test.

RESULTS

| Test | substance | 1 | Aniline |
|------|---------------|-----|---------------|
| Day | % degradation | Day | % degradation |
| 4 | 10 | 4 | 19 |
| 14 | 76 | 14 | 71 |
| 21 | 84 | 21 | 75 |

Remarks - Results The pH and temperatures were within acceptable range. The test material

attained 88% degradation after 28 days. The 10-day window criterion was satisfied. The reference substance attained 71% degradation after 14 days

and 76% after 28 days and thus validating the test system.

CONCLUSION The notified chemical is considered to be readily biodegradable.

TEST FACILITY SafePharm (2004k)

C.1.2. Bioaccumulation

Given the rapid hydrolysis in contact with water and the ready biodegradation of the notified chemical, it has little potential to bioaccumulate.

C.2. Ecotoxicological Investigations

C.2.1. Acute toxicity to fish

TEST SUBSTANCE Notified chemical

METHOD OECD TG 203 Fish, Acute Toxicity Test –semi static.

EC Directive 92/69/EEC C.1 Acute Toxicity for Fish, semi-static.

Rainbow trout (Oncorhynchus mykiss) Species

Exposure Period 96 h Auxiliary Solvent None

Water Hardness 100 mg CaCO₃/L

Analytical Monitoring

Remarks - Method

Following a range-finding test, 2 groups of 10 fish were exposed to a nominal test concentration of 100 mg/L and 10 fish to a control for a period of 96 h under semi-static conditions. The media were renewed daily. The test material was stirred in diluent for 24 h to allow hydrolysis of the test substance. The test material dispersion was filtered prior to the test in order to remove any undissolved test substance that may have exerted a physical effect on the test organisms. Concentrations of hydrolysis products were used to determine the stability and concentrations of the test solutions at 0 and 24 h. The mortalities and sublethal effects were determined at 3, 6, 24, 48, 72 and 96 h after the start of exposure. The temperature, pH and dissolved oxygen were recorded daily throughout the test.

RESULTS

| Concentration mg/L | Number of Fish | | - | Mortality | • | |
|--------------------|----------------|----|-----|-----------|-----|-----|
| Nominal | | 3h | 24h | 48h | 72h | 96h |
| 0 | 10 | 0 | 0 | 0 | 0 | 0 |
| 100 | 10 | 0 | 0 | 0 | 0 | 0 |
| 100 | 10 | 0 | 0 | 0 | 0 | 0 |

>100 mg/L at 96 hours. LC_{50} **NOEC** 100 mg/L at 96 hours.

Remarks - Results The temperature, pH and dissolved oxygen were within acceptable range.

Analysis of one hydrolysis product's concentration for fresh and 24 h old samples indicated 73-77% and 67-79% of the theoretical concentration, respectively. Analysis of another hydrolysis product's concentration for fresh and 24 h old samples indicated 69-96% and 62-83% of the theoretical concentration, respectively. The hydrolysis products were stable in the test medium for the duration of the period of media renewal. The test solutions were observed to be clear, colourless solution throughout the test. Neither mortalities nor sub-lethal effects were observed in the test solution or the control during the 96 h exposure. Given that toxicity cannot be attributed to any one, or more, of the hydrolysis products, the results are based on nominal concentrations of

the test substance alone.

CONCLUSION The test substance is considered to be non-toxic to fish.

TEST FACILITY SafePharm (2005a)

C.2.2. Acute toxicity to aquatic invertebrates

Notified chemical TEST SUBSTANCE

METHOD EC Directive 92/69/EEC C.2 Acute Toxicity for Daphnia - static.

OECD TG 202 Daphnia sp, Acute immobilisation test and reproduction

Daphnia magna Species

Exposure Period 48 hours Auxiliary Solvent None

Water Hardness 250 mg CaCO₃/L

Analytical Monitoring GC.

Remarks - Method

Following a range-finding test, 10 daphnids in duplicate were exposed to nominal test concentrations of 1.0, 1.8, 3.2, 5.6, 10, 18, 32, 56 and 100 mg/L and a control group for a period of 48 h under static conditions. The test material was stirred in diluent for 24 h to allow hydrolysis of the test substance. The test material dispersion was filtered prior to the test in order to remove any undissolved test substance that may have exerted a physical effect on the test organisms. Concentrations of hydrolysis products were used to determine the stability and concentrations of the test solutions at each time point. Any immobilisation of daphnids was recorded at 24 and 48 h after the start of exposure. The temperature, pH and dissolved oxygen were recorded throughout the test. The EC₅₀ and confidence limits at 24 and 48 h were calculated by probit analysis method.

RESULTS

| Concentration (mg/L) | | Number of D. magne | Number In | Number Immobilised | |
|----------------------|---------|---------------------------|-----------|--------------------|--|
| Nominal | Actual* | <i>Number of</i> D. magna | 24 h | 48 h | |
| 0 (control) | 0 | 20 | 0 | 0 | |
| 1.0 | 64-77% | 20 | 0 | 0 | |
| 1.8 | 64-77% | 20 | 0 | 0 | |
| 3.2 | 64-77% | 20 | 0 | 0 | |
| 5.6 | 64-77% | 20 | 0 | 0 | |
| 10 | 64-77% | 20 | 0 | 0 | |
| 18 | 64-77% | 20 | 0 | 0 | |
| 32 | 64-77% | 20 | 15 | 45 | |
| 56 | 64-77% | 20 | 55 | 90 | |
| 100 | 64-77% | 20 | 75 | 100 | |

^{*}The actual values were based on the measured concentrations of a single hydrolysis product as a % of the theoretical values.

EC50 35 mg/L (CI: 30-41 mg/L) at 48 hours

NOEC 18 mg/L at 48 hours

Remarks – Results The temperature, pH and dissolved oxygen were within acceptable range.

The measured concentrations of each hydrolysis product at each time point were shown to be in excess of 77% of the theoretical concentration. The hydrolysis products were stable in the test medium for the duration of the exposure period. The test solutions were observed to be clear, colourless solution throughout the test. 15% immobilisation was observed at a nominal test concentration of 32 mg/L and complete immobilisation occurred at 100 mg/L. Given that toxicity cannot be attributed to any one, or more, of the hydrolysis products, the results are based on nominal

concentrations of the test substance alone.

CONCLUSION The test substance is considered to be harmful to *Daphnia magna*

TEST FACILITY SafePharm (2004m)

C.2.3. Algal growth inhibition test

TEST SUBSTANCE Notified chemical

METHOD OECD TG 201 Alga, Growth Inhibition Test.

EC Directive 92/69/EEC C.3 Algal Inhibition Test.

Species Green alga (Scenedesmus subspicatus)

Exposure Period 72 hours

Concentration Range Nominal: 1.0-320 mg/L

Auxiliary Solvent None Water Hardness None Analytical Monitoring None

Remarks - Method Following a range-finding test, algae were exposed to nominal test

concentrations of 1.0, 3, 10, 32, 100 and 320 mg/L and a control group in triplicates for a period of 72 h under constant illumination and shaking. The test material was stirred in diluent for 24 h to allow hydrolysis of the test substance. The test material dispersion was filtered prior to the test in order to remove any undissolved test substance that may have exerted a physical effect on the test organisms. Concentrations of the hydrolysis products were used to determine the stability and concentrations of the test solutions at 0 and 72 h. Samples of the algal populations were removed daily and cell densities were determined for each control and treatment groups. The temperature and pH were recorded throughout the test. Statistical analyses were performed by one-way analysis of variance incorporating Bartlett's test for homogeneity of variance and Dunnett's multiple comparison procedure.

RESULTS

| Biom | ass | Grow | th |
|-------------------------|---|--|--|
| EbC_{50} mg/L at 72 h | NOEC mg/L | ErC_{50} mg/L at 72 h | $NOEC\ mg/L$ |
| 7.3 | 1.0 | >320 mg/L | 1.0 |
| Remarks - Results | cultures and con and 1.0 mg/L test green dispersion extremely pale go clear colourless decline in the appears to be dowere considered period. It was not as the data generattributed to any | e and pH were within acceptable trol were clear colourless solutions to cultures were green dispersion as and the 10, 32 and 100 magnetic dispersions. The 320 mg/L solutions throughout the test permeasured concentrations of higher than the test medium for the possible to calculate confidentiated did not fit the models. Given one, or more, of the hydrolysis all concentrations of the test substitute of the concentration of the concentrations of the conc | ons. After 72 h the control s, the 3.2 mg/L were pale mg/L test cultures were test cultures remained as teriod. At 72 h there were ydrolysis products. This The hydrolysis products duration of the exposure tee limits for EC ₅₀ values en that toxicity cannot be a products, the results are |
| Conclusion | The test substar ErC ₅₀ of >320 m | nce is considered to be non-to- | xic to alga based on the |
| TEST FACILITY | SafePharm (200 | 5b) | |

C.2.4. Inhibition of microbial activity

TEST SUBSTANCE

| METHOD | OECD TG 209 Activated Sludge, Respiration Inhibition Test. |
|--------|--|

XP 339

EC Directive 87/302/EEC C.11 Biodegradation: Activated Sludge

Respiration Inhibition Test

US EPA Draft Ecological effects test guidelines OPPTS 850.6800

Inoculum A mixture of activated sewage sludge and synthetic sludge which acts as

a respiratory substrate.

Exposure Period 3 hours
Concentration Range Nomina
Remarks – Method Based of

Nominal: 1000 mg/L

Based on the range-finding tests' results, test organisms were exposed to a nominal concentrations of 1000 mg/L in triplicates and a control group in duplicates. A reference material, 3,5-dichlorophenol at concentrations of 3.2, 10 and 32 mg/L was used to validate the test. The test organisms were exposed to the test solutions for a contact time of 30 minutes and 3 h. The test material was stirred for 96 h at 21°C in sterile diluent to allow hydrolysis to occur. The test material dispersion was filtered prior to the

test in order to remove any undissolved test substance that may have exerted a physical effect on the test organisms. The pH was recorded for the test substance, control and reference substance throughout the test. The EC_{50} for the test substance was determined by inspection of the inhibition of respiration rate data.

RESULTS

 IC_{50} >1000 mg/L at 3 h

NOEC 1000 mg/L

At the nominal concentration of 1000 mg/L, no undissolved test material

was visible.

CONCLUSION The test substance is considered to be non-toxic to sewage

microorganisms.

TEST FACILITY SafePharm (2004n)

BIBLIOGRAPHY

- FedChem (2003a) IR, UV and Melting Point Determinations for XP 338. FedChem LLC, Bethlehem, PA, USA (unpublished report provided by the notifier).
- FedChem (2003b) ¹H and ¹³C NMR for XP 338. FedChem LLC, Bethlehem, PA, USA (unpublished report provided by the notifier).
- FedChem (2003c) Hydrolysis of XP 338 as a Function of pH. FedChem LLC, Bethlehem, PA, USA (unpublished report provided by the notifier).
- FedChem (2003d) Brookfield Viscosity. FedChem LLC, Bethlehem, PA, USA (unpublished report provided by the notifier).
- FORS (Federal Office of Road Safety) (1998) Australian Code for the Transport of Dangerous Goods by Road and Rail (ADG code), 6th Edition, Canberra, Australian Government Publishing Service
- Impact Analytical (2003) Analysis of XP 338 and XP 339; Report R03-0179; Impact Analytical, 1910 West Saint Andrews Road, Midland, MI, USA (unpublished report provided by the notifier).
- NOHSC (1994) National Code of Practice for the Labelling of Workplace Substances [NOHSC:2012(1994)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- NOHSC (2004) Approved Criteria for Classifying Hazardous Substances, 3rd edition [NOHSC:1008(2004)]. National Occupational Health and Safety Commission, Canberra, AusInfo.
- NOHSC (2003) National Code of Practice for the Preparation of Material Safety Data Sheets, 2nd edition [NOHSC:2011(2003)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- Robertson Microlit Laboratories (2003) Microanalysis Report for XP 338. Robertson Microlit Laboratories, 29 Samson Ave, Madison, NJ, USA (unpublished report provided by the notifier).
- SafePharm (2004a) XP 338: Determination of General Physico-Chemical Properties. Project number 1922/014. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004b) XP 338: Determination of Hazardous Physico-Chemical Properties. Project number 1922/015. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004c) XP 338: Acute Oral Toxicity in the Rat Acute Toxic Class Method. Project number 1922/016. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004d) XP 339: Acute Dermal Toxicity (Limit Test) in the Rat. Project number 1922/004. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004e) XP 339: Acute Dermal Irritation in the Rabbit. Project number 1922/005. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004f) XP 339: Acute Eye Irritation in the Rabbit. Project number 1922/006. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004g) XP 339: Local Lymph Node Assay in the Mouse. Project number 1922/007. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004h) XP 339: Ninety Day Repeated Dose Oral (Gavage) Toxicity Study in the Rat. Project number 1922/008. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004i) XP 338: Reverse Mutation Assay 'Ames Test' Using *Salmonella typhimurium*. Project number 1922/017. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004j) XP 339: Chromosome Aberration Test in Human Lymphocytes *in vitro*. Project number 1922/009. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).

SafePharm (2004k) XP 338: Assessment of Ready Biodegradability: Manometric Respirometry Test. Project number 1922/019. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).

- SafePharm (2004m) XP 338: Acute Toxicity to *Daphnia Magna*. Project number 1922/018. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2004n) XP 339: Assessment of the Inhibitory Effect on the Respiration of Activated Sewage Sludge. Project number 1922/013; Safepharm Laboratories Ltd., Shardlow, Derbyshire, UK (unpublished report provided by the notifier).
- SafePharm (2005a) XP 338: Acute Toxicity to Rainbow Trout. Project number 1922/020. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- SafePharm (2005b) XP 338: Algal Inhibition Test. Project number 1922/021. Safepharm Laboratories Ltd., Shardlow, Derbyshire UK (unpublished report provided by the notifier).
- United Nations (2003) Globally Harmonised System of Classification and Labelling of Chemicals (GHS). United Nations Economic Commission for Europe (UN/ECE), New York and Geneva.